Multiple endocrine neoplasia type 2 future or investigational therapies

Revision as of 02:46, 27 November 2017 by Mmir (talk | contribs) (Mahshid)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Multiple endocrine neoplasia type 2 Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple endocrine neoplasia type 2 from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

Diagnostic Criteria

History & Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Multiple endocrine neoplasia type 2 future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple endocrine neoplasia type 2 future or investigational therapies

CDC on Multiple endocrine neoplasia type 2 future or investigational therapies

Multiple endocrine neoplasia type 2 future or investigational therapies in the news

Blogs on Multiple endocrine neoplasia type 2 future or investigational therapies

Directions to Hospitals Treating Multiple endocrine neoplasia type 2

Risk calculators and risk factors for Multiple endocrine neoplasia type 2 future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Future or investigational therapies of multiple endocrine neoplasia type 2 include treatment with axitinib, gefitinib, imatinib, motesanib, sorafenib, sunitinib, vandetanib and XL184.

Future or investigational therapies

Further studies on the molecular pathways of c-RET gene and its protein will help to design novel and more individualized therapeutic modalities based on genetic information. In fact, although the knowledge about mechanisms of tumor development in patients with multiple endocrine neoplasia type 2 has grown tremendously, much work lies ahead. The final goal is to offer patients with c-RET germline mutations an optimal cancer prevention and treatment program. Table below list the major drugs that are being investigated for the treatment of multiple endocrine neoplasia type 2.

Ongoing trials
Drug Target molecule
Axitinib VEGFR, PDGFR beta, C. Kit
Gefitinib EGFR
Imatinib VEGFR, RET, BCR-ABL
Motesanib VEGFR, RET, PDGFR beta, C. Kit
Sorafenib VEGFR, RET, RET/PTC, BRAF, PDGFR beta, C. Kit
Sunitinib VEGFR, RET, RET/PTC, PDGFR beta
Vandetanib VEGFR, RET, RET/PTC, EGFR
XL184 VEGFR, RET, PDGFR beta
Adapted from C. Romei, E. Pardi, F. Cetani, and R. Elisei Genetic and Clinical Features of Multiple Endocrine Neoplasia Types 1 and 2, Journal of Oncology, vol. 2012, Article ID 705036, 15 pages, 2012. doi:10.1155/2012/705036[1]

References

  1. Romei C, Pardi E, Cetani F, Elisei R (2012). "Genetic and clinical features of multiple endocrine neoplasia types 1 and 2". J Oncol. 2012: 705036. doi:10.1155/2012/705036. PMC 3503399. PMID 23209466.

​​​


Template:WikiDoc Sources